Introduction {#jcmm12836-sec-0001}
============

Neuroblastoma has been recognized as the most common childhood extracranial solid tumour, and the third leading cause of tumour‐related death in children [1](#jcmm12836-bib-0001){ref-type="ref"}. The incidence peaks in infancy with a median age at diagnosis of approximately 17 months [2](#jcmm12836-bib-0002){ref-type="ref"}. Despite the utilization of multiple modality treatment involving intensive chemotherapy, radiotherapy and autologous bone marrow transplantation, cure rates for high‐risk patients remain 40% or less. Survivors are frequently subject to serious lifelong coexisting conditions and have poor outcomes [3](#jcmm12836-bib-0003){ref-type="ref"}. With the incidence rate of about 7.7 per million, neuroblastoma is the fourth most frequently diagnosed solid tumour in Chinese children after CNS tumours, lymphomas and germ cell tumours (incidence rate: 23.8, 11.0 and 7.8 per million, respectively) [4](#jcmm12836-bib-0004){ref-type="ref"}. Neuroblastoma is a worldwide public health problem. To date, common environmental exposures that can increase neuroblastoma risk have not been well documented [5](#jcmm12836-bib-0005){ref-type="ref"}, [6](#jcmm12836-bib-0006){ref-type="ref"}. It was suggested that fathers who exposed to some factors (*e.g*., wood dust, solders, radiation sources and hydrocarbons) were more likely to have children with neuroblastoma [5](#jcmm12836-bib-0005){ref-type="ref"}, [6](#jcmm12836-bib-0006){ref-type="ref"}. However, even if fathers were exposed to the same risk environment, only a small proportion of their offspring finally developed neuroblastoma, indicating that genetic factors (*e.g*., polymorphism) may also contribute to neuroblastoma [6](#jcmm12836-bib-0006){ref-type="ref"}.

Genome‐wide association studies (GWASs) have provided evidence that common genetic variants are associated with neuroblastoma susceptibility, with several neuroblastoma susceptibility loci identified [7](#jcmm12836-bib-0007){ref-type="ref"}, [8](#jcmm12836-bib-0008){ref-type="ref"}, [9](#jcmm12836-bib-0009){ref-type="ref"}, [10](#jcmm12836-bib-0010){ref-type="ref"}, [11](#jcmm12836-bib-0011){ref-type="ref"}. In the first GWAS for neuroblastoma, a total of 1032 neuroblastoma patients and 2043 controls of European descent were genotyped by using Illumina HumanHap550 BeadChip covering approximately 500,000 single nucleotide polymorphisms (SNPs). Sequentially, an addition of 720 patients and 2128 controls were tested to further validate significant SNPs identified using first‐stage data. The two‐stage GWAS discovered that three SNPs (rs6939340 A\>G, rs4712653 T\>C and rs9295536 C\>A) within the *CASC15* gene at 6p22 were associated with neuroblastoma susceptibility [7](#jcmm12836-bib-0007){ref-type="ref"}. The association between these three SNPs and neuroblastoma susceptibility has been verified by studies with different ethnicities, such as African--Americans [12](#jcmm12836-bib-0012){ref-type="ref"}, Italians [13](#jcmm12836-bib-0013){ref-type="ref"}, Northern Chinese population [14](#jcmm12836-bib-0014){ref-type="ref"} and Southern Chinese children [15](#jcmm12836-bib-0015){ref-type="ref"}. We previously confirmed the association of the three SNPs with decreased neuroblastoma risk in Southern Chinese children with a total of 201 neuroblastoma cases and 531 cancer‐free controls [15](#jcmm12836-bib-0015){ref-type="ref"}. GWASs serve as a powerful and important tool to discover inherited common genetic variations for human diseases including cancer [16](#jcmm12836-bib-0016){ref-type="ref"}, [17](#jcmm12836-bib-0017){ref-type="ref"}. It can identify genes previously not implicated in cancer susceptibility by utilizing an agnostic approach. Thus, because of the adoption of restricted *P*‐value (1 × 10^−5^), most of the GWAS‐identified SNPs only have modest risk effects, usually with odds ratio (OR) ranging from 1.1 to 1.5 [17](#jcmm12836-bib-0017){ref-type="ref"}. Moreover, the majority of them were located in the intron regions without function. Polymorphisms in the candidate genes, especially functional SNPs, represent a more meaningful way to investigate the role of genes in cancer risk. Previous studies have identified several neuroblastoma risk loci in Chinese populations, such as functional polymorphisms in the *FAS*/*FASL* system genes [18](#jcmm12836-bib-0018){ref-type="ref"} and *TGFBR3L* gene [19](#jcmm12836-bib-0019){ref-type="ref"}.

DNA repair genes play critical roles in maintaining the integrity and stability of genomic DNA, and about 130 genes have been reported to be involved in the five major DNA repair pathways, including nucleotide excision repair (NER) pathway [20](#jcmm12836-bib-0020){ref-type="ref"}. The NER pathway are mainly responsible for the removing of DNA adducts and lesions [21](#jcmm12836-bib-0021){ref-type="ref"}. In humans, xeroderma pigmentosum group G/excision repair cross‐complementation group 5 (XPG/ERCC5, MIM:133530) is a member of the xeroderma pigmentosum complementation groups (XPA, XPB, XPC, XPD, XPE, XPF and XPG) [22](#jcmm12836-bib-0022){ref-type="ref"}. It functions as an endonuclease and cuts the damaged DNA at the 3′ ends of lesions during the process of DNA repair [23](#jcmm12836-bib-0023){ref-type="ref"}. Thus far, investigations for the association between *XPG* gene polymorphisms and cancer susceptibility have mainly focused on rs17655G\>C polymorphism (Asp1104His) and conclusions were controversial [24](#jcmm12836-bib-0024){ref-type="ref"}. The associations of potentially functional polymorphisms in the *XPG* gene with neuroblastoma susceptibility have not been investigated yet. With these in mind, we performed this study including 256 neuroblastoma cases and 531 cancer‐free controls from Southern Chinese children to investigate the association between five potentially functional polymorphisms (rs2094258 C\>T, rs751402 C\>T, rs2296147 T\>C, rs1047768 T\>C and rs873601G\>A) and neuroblastoma susceptibility.

Materials and methods {#jcmm12836-sec-0002}
=====================

Study subjects {#jcmm12836-sec-0003}
--------------

The current retrospective hospital‐based case--control study consisted of 256 patients with newly diagnosed and histopathologically confirmed neuroblastoma. Patients were enrolled from the Department of Pediatric Surgery, Guangzhou Women and Children\'s Medical Center, mainly between February 2010 and November 2015. We also recruited 531 age‐, gender‐, and ethnicity‐matched cancer‐free controls from the same geographical regions (Table S1) as described previously [15](#jcmm12836-bib-0015){ref-type="ref"}, [25](#jcmm12836-bib-0025){ref-type="ref"}. Written informed consent was obtained from each subject or his/her guardian. The response rate was about 90% for neuroblastoma subjects and 95% for cancer‐free controls. The study protocol was approved by the Institutional Review Board of Guangzhou Women and Children\'s Medical Center.

SNP selection and genotyping {#jcmm12836-sec-0004}
----------------------------

As shown in Table S2, we chose five potentially functional *XPG* SNPs (located in the 5′‐ flanking region, 5′ UTR, exon and 3′ UTR) in this study. Of them, three (rs2094258 C\>T, rs2296147 T\>C and rs873601G\>A) were reported as potentially functional SNPs in a previous investigation [26](#jcmm12836-bib-0026){ref-type="ref"}. The rs751402 C\>T polymorphism located in the 5′ UTR was also reported in another study [27](#jcmm12836-bib-0027){ref-type="ref"}. Besides, we chose rs1047768 T\>C since it can lead to splicing alteration as predicted by online website SNPinfo (<http://snpinfo.niehs.nih.gov/>). The widely studied rs17655G\>C polymorphism was not included in this study because of strong evidence of linkage disequilibrium between this SNP and rs873601G\>A polymorphism (*R* ^2^ = 0.91). All of these chosen polymorphisms had a minor allele frequency \>5% in Chinese Han subjects. Single nucleotide polymorphism genotyping was performed in 384‐well plates using Taqman methodology as described elsewhere [15](#jcmm12836-bib-0015){ref-type="ref"}, [26](#jcmm12836-bib-0026){ref-type="ref"}.

Genotype--phenotype correlation analysis {#jcmm12836-sec-0005}
----------------------------------------

We performed genotype--phenotype correlation analysis in order to provide biological evidence for our findings. We explored the effects of *XPG* SNPs on gene expression by evaluating the correlation between genotype data of 270 individuals from HapMap phase II release 23 data set containing genotypes of 3.96 million SNPs from four populations (<http://hapmap.ncbi.nlm.nih.gov/>), and corresponding *XPG* gene transcripts from EBV‐transformed B lymphoblastoid cell lines of the same 270 subjects from SNPexp (<http://app3.titan.uio.no/biotools/help.php?app5snpexp>). The four populations were as follows: CEU: 90 Utah residents with ancestry from northern and western Europe; CHB: 45 unrelated Han Chinese in Beijing; JPT: 45 unrelated Japanese in Tokyo; YRI: 90 Yoruba in Ibadan, Nigeria. For more details on the study subjects and methodology, refer to previous publications [26](#jcmm12836-bib-0026){ref-type="ref"}, [28](#jcmm12836-bib-0028){ref-type="ref"}, [29](#jcmm12836-bib-0029){ref-type="ref"}.

Statistical analysis {#jcmm12836-sec-0006}
--------------------

Distributions of demographic variables and genotype frequencies in neuroblastoma cases and controls were evaluated using chi‐squared test. Hardy--Weinberg equilibrium (HWE) was calculated for controls using the goodness‐of‐chi‐squared test. Odds ratios and corresponding 95% confidence intervals (CIs) were used to estimate the association between selected polymorphisms and neuroblastoma risk. Adjusted ORs were calculated by multivariate analysis with unconditional logistic regression, with adjustment for age and gender. We also computed the false‐positive report probability (FPRP) values for the significant findings. We set 0.2 as FPRP threshold and adopt a prior probability of 0.1 to detect OR of 1.50/0.67 (risk/protective effects) as described previously [30](#jcmm12836-bib-0030){ref-type="ref"}, [31](#jcmm12836-bib-0031){ref-type="ref"}. The association that reached the FPRP threshold of \<0.2 was considered noteworthy. All statistical tests were two‐sided, with a significance level of *P* \< 0.05. All statistical analyses were performed using SAS software (Version 9.1; SAS Institute, Cary, NC, USA).

Results {#jcmm12836-sec-0007}
=======

Demographic characteristics of the subjects {#jcmm12836-sec-0008}
-------------------------------------------

Demographic characteristics of the neuroblastoma cases and cancer‐free controls were presented in Table S1. We included 256 neuroblastoma patients and 531 cancer‐free controls in this study. There were no significant differences in age (*P* = 0.239) and gender (*P* = 0.333) between the two groups. According to the INSS criteria [32](#jcmm12836-bib-0032){ref-type="ref"}, there were 54 (21.09%), 65 (25.39%), 44 (17.19%), 77 (30.08) and 9 (3.52%) patients with clinical I, II, III, IV and 4s neuroblastoma, respectively. In term of site, 46 (17.97%) neuroblastoma occurred in the adrenal gland, 87 (33.98%) in the retroperitoneal and 90 (35.16%) in the mediastinum.

Associations between XPG gene polymorphisms and neuroblastoma risk {#jcmm12836-sec-0009}
------------------------------------------------------------------

Of the enrolled subjects, 248 neuroblastoma cases and 531 cancer‐free controls were successfully genotyped. The allele and genotype frequencies of the selected SNPs and their associations with neuroblastoma risk are summarized in Table [1](#jcmm12836-tbl-0001){ref-type="table-wrap"}. All of the genotype distributions for the five selected polymorphisms were consistent with the HWE (*P* = 0.701 for rs2094258 C\>T, *P* = 0.380 for rs751402 C\>T, *P* = 0.583 for rs2296147 T\>C, *P* = 0.409 for rs1047768 T\>C and *P* = 0.686 for rs873601G\>A) in control subjects. When compared with the rs2094258 CC genotype, the variant CT and CT/TT genotypes were significantly associated with decreased neuroblastoma risk (CT *versus* CC: adjusted OR = 0.65, 95% CI = 0.47--0.90, *P* = 0.010; and CT/TT *versus* CC: adjusted OR = 0.71, 95% CI = 0.53--0.97, *P* = 0.030) after adjusting for age and gender. We also observed a borderline statistically significantly increased neuroblastoma risk in the carriers of the rs1047768 C allele (CC *versus* TT: adjusted OR = 1.73, 95% CI = 0.93--3.21, *P* = 0.083; and CC *versus* TT/CT: adjusted OR = 1.68, 95% CI = 0.92--3.08, *P* = 0.092). However, there was no significant association or trend observed between the rest of the three polymorphisms and neuroblastoma risk (Table [1](#jcmm12836-tbl-0001){ref-type="table-wrap"}). Compared to the subjects without risk genotype, we found a significant trend toward increased risk for subjects carrying 0--3 risk genotypes (adjusted OR = 1.29, 95% CI = 1.06--1.56, *P* = 0.011). We also observed carriers of 2--3 risk genotypes were significantly more predisposed to developing neuroblastoma when compared to carriers of 0--1 risk genotypes (adjusted OR = 1.47, 95% CI = 1.08--1.99, *P* = 0.013).

###### 

Logistic regression analysis of the association between the five polymorphisms in *XPG* gene and neuroblastoma susceptibility

  Genotype                            Cases (*N* = 248)   Controls (*N* = 531)   *P* [\*](#jcmm12836-note-0002){ref-type="fn"}   Crude OR (95% CI)       *P*         Adjusted OR (95% CI)[†](#jcmm12836-note-0002){ref-type="fn"}   *P* [†](#jcmm12836-note-0002){ref-type="fn"}
  ----------------------------------- ------------------- ---------------------- ----------------------------------------------- ----------------------- ----------- -------------------------------------------------------------- ----------------------------------------------
  rs2094258 C\>T (HWE = 0.701)                                                                                                                                                                                                      
  CC                                  116 (46.77)         203 (38.23)                                                            1.00                                1.00                                                           
  CT                                  93 (37.50)          254 (47.83)                                                            **0.64 (0.46--0.89)**   **0.008**   **0.65 (0.47--0.90)**                                          **0.010**
  TT                                  39 (15.73)          74 (13.94)                                                             0.92 (0.59--1.45)       0.725       0.94 (0.60--1.47)                                              0.770
  Additive                                                                       0.024                                           0.87 (0.70--1.08)       0.208       0.88 (0.70--1.09)                                              0.237
  Dominant                            132 (53.23)         328 (61.77)            0.024                                           **0.70 (0.52--0.96)**   **0.024**   **0.71 (0.53--0.97)**                                          **0.030**
  Recessive                           209 (84.27)         457 (86.06)            0.509                                           1.15 (0.76--1.76)       0.509       1.16 (0.76--1.77)                                              0.482
  rs751402 C\>T (HWE = 0.380)                                                                                                                                                                                                       
  CC                                  96 (38.71)          208 (39.17)                                                            1.00                                1.00                                                           
  CT                                  114 (45.97)         241 (45.39)                                                            1.03 (0.74--1.42)       0.883       1.02 (0.73--1.41)                                              0.922
  TT                                  38 (15.32)          82 (15.44)                                                             1.00 (0.64--1.58)       0.986       0.99 (0.63--1.56)                                              0.969
  Additive                                                                       0.988                                           1.01 (0.81--1.25)       0.949       1.00 (0.81--1.24)                                              1.000
  Dominant                            152 (61.29)         323 (60.83)            0.902                                           1.02 (0.75--1.39)       0.902       1.01 (0.74--1.38)                                              0.950
  Recessive                           210 (84.68)         449 (84.56)            0.966                                           0.99 (0.65--1.51)       0.966       0.98 (0.65--1.49)                                              0.933
  rs2296147 T\>C (HWE = 0.583)                                                                                                                                                                                                      
  TT                                  160 (64.52)         343 (64.60)                                                            1.00                                1.00                                                           
  CT                                  79 (31.85)          170 (32.02)                                                            1.00 (0.72--1.38)       0.982       0.99 (0.71--1.37)                                              0.950
  CC                                  9 (3.63)            18 (3.39)                                                              1.07 (0.47--2.44)       0.867       1.08 (0.47--2.45)                                              0.860
  Additive                                                                       0.985                                           1.01 (0.77--1.33)       0.940       1.01 (0.77--1.32)                                              0.960
  Dominant                            88 (35.48)          188 (35.40)            0.983                                           1.00 (0.73--1.38)       0.983       1.00 (0.73--1.37)                                              0.990
  Recessive                           239 (96.37)         513 (96.61)            0.865                                           1.07 (0.48--2.43)       0.863       1.08 (0.48--2.44)                                              0.853
  rs1047768 T\>C (HWE = 0.409)                                                                                                                                                                                                      
  TT                                  135 (54.44)         307 (57.82)                                                            1.00                                1.00                                                           
  CT                                  93 (37.50)          198 (37.29)                                                            1.07 (0.78--1.47)       0.685       1.07 (0.78--1.47)                                              0.679
  CC                                  20 (8.06)           26 (4.90)                                                              1.75 (0.94--3.24)       0.076       1.73 (0.93--3.21)                                              0.083
  Additive                                                                       0.200                                           1.19 (0.93--1.52)       0.161       1.19 (0.93--1.52)                                              0.168
  Dominant                            113 (45.56)         224 (42.18)            0.375                                           1.15 (0.85--1.55)       0.375       1.15 (0.85--1.55)                                              0.378
  Recessive                           228 (91.94)         505 (95.10)            0.081                                           1.70 (0.93--3.12)       0.084       1.68 (0.92--3.08)                                              0.092
  rs873601G\>A (HWE = 0.686)                                                                                                                                                                                                        
  GG                                  70 (28.23)          137 (25.80)                                                            1.00                                1.00                                                           
  AG                                  112 (45.16)         270 (50.85)                                                            0.81 (0.57--1.17)       0.260       0.82 (0.57--1.18)                                              0.276
  AA                                  66 (26.61)          124 (23.35)                                                            1.04 (0.69--1.58)       0.847       1.07 (0.70--1.62)                                              0.767
  Additive                                                                       0.329                                           1.02 (0.82--1.26)       0.879       1.03 (0.83--1.27)                                              0.803
  Dominant                            178 (71.77)         394 (74.20)            0.475                                           0.88 (0.63--1.24)       0.475       0.89 (0.64--1.26)                                              0.518
  Recessive                           182 (73.39)         407 (76.65)            0.324                                           1.19 (0.84--1.68)       0.324       1.21 (0.86--1.72)                                              0.279
  Combined effect of risk genotypes                                                                                                                                                                                                 
  0                                   27 (10.89)          82 (15.44)                                                             1.00                                1.00                                                           
  1                                   95 (38.31)          231 (43.50)                                                            1.25 (0.76--2.05)       0.380       1.25 (0.76--2.06)                                              0.375
  2                                   110 (44.35)         191 (35.97)                                                            **1.75 (1.07--2.87)**   **0.027**   **1.73 (1.06--2.84)**                                          **0.030**
  3                                   16 (6.45)           27 (5.08)                                                              1.80 (0.85--3.83)       0.128       1.81 (0.85--3.86)                                              0.125
  Trend                                                                          0.010                                           **1.29 (1.06--1.57)**   **0.010**   **1.29 (1.06--1.56)**                                          **0.011**
  0--1                                122 (49.19)         313 (58.95)                                                            1.00                                1.00                                                           
  2--3                                126 (50.81)         218 (41.05)            0.011                                           **1.48 (1.10--2.01)**   **0.011**   **1.47 (1.08--1.99)**                                          **0.013**

The significant results were in bold, if the 95% CI excluded 1 or *P* \<0.05. \*Chi‐squared test for genotype distributions between neuroblastoma patients and controls. ^†^Adjusted for age and gender.
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Stratified analysis {#jcmm12836-sec-0010}
-------------------

We performed subgroup analyses by age, gender, tumour sites of origin and clinical stages to evaluate the effects of rs2094258 C\>T polymorphism and combined risk genotypes on the risk of neuroblastoma (Table [2](#jcmm12836-tbl-0002){ref-type="table-wrap"}). We found that the rs2094258 CT/TT genotypes were significantly associated with a decreased neuroblastoma risk in subjects with tumour in the retroperitoneal (adjusted OR = 0.54, 95% CI = 0.33--0.86, *P* = 0.010) and subjects with early‐stage tumour (adjusted OR = 0.55, 95% CI = 0.37--0.81, *P* = 0.003). When the risk genotypes were combined, the significant association with 2--3 risk genotypes were observed in older children (adjusted OR = 1.49, 95% CI = 1.003--2.21, *P* = 0.049), girls (adjusted OR = 1.74, 95% CI = 1.08--2.79, *P* = 0.023), subjects with retroperitoneal tumour (adjusted OR = 2.13, 95% CI = 1.32--3.45, *P* = 0.002), and those with early‐stage tumour (adjusted OR = 2.11, 95% CI = 1.42--3.15, *P* = 0.0003).

###### 

Stratification analysis of the *XPG* rs2094258 C\>T polymorphism and combined risk genotypes with neuroblastoma susceptibility

  Variables         rs2094258 (cases/controls)   OR (95% CI)   *P*                     Adjusted OR[\*](#jcmm12836-note-0003){ref-type="fn"} (95% CI)   *P* [\*](#jcmm12836-note-0003){ref-type="fn"}   Combined    OR (95% CI)   *P*      Adjusted OR[\*](#jcmm12836-note-0003){ref-type="fn"} (95% CI)   *P* [\*](#jcmm12836-note-0003){ref-type="fn"}                            
  ----------------- ---------------------------- ------------- ----------------------- --------------------------------------------------------------- ----------------------------------------------- ----------- ------------- -------- --------------------------------------------------------------- ----------------------------------------------- ------------------------ ------------
  Age, month                                                                                                                                                                                                                                                                                                                                                                       
  ≤18               44/86                        53/147        0.71 (0.44--1.14)       0.153                                                           0.71 (0.44--1.14)                               0.155       48/137        49/96    1.46 (0.91--2.35)                                               0.121                                           1.45 (0.90--2.34)        0.126
  \>18              72/117                       79/181        0.71 (0.48--1.05)       0.088                                                           0.72 (0.48--1.06)                               0.098       74/176        77/122   **1.50 (1.01--2.23)**                                           **0.043**                                       **1.49 (1.003--2.21)**   **0.049**
  Gender                                                                                                                                                                                                                                                                                                                                                                           
  Females           45/81                        55/152        0.65 (0.40--1.05)       0.078                                                           0.65 (0.41--1.05)                               0.081       50/148        50/85    **1.74 (1.08--2.80)**                                           **0.022**                                       **1.74 (1.08--2.79)**    **0.023**
  Males             71/122                       77/176        0.75 (0.51--1.12)       0.159                                                           0.76 (0.51--1.13)                               0.169       72/165        76/133   1.31 (0.88--1.94)                                               0.181                                           1.31 (0.88--1.94)        0.187
  Sites of origin                                                                                                                                                                                                                                                                                                                                                                  
  Adrenal gland     23/203                       23/328        0.62 (0.34--1.13)       0.119                                                           0.65 (0.36--1.20)                               0.172       23/313        23/218   1.44 (0.79--2.63)                                               0.240                                           1.37 (0.75--2.51)        0.311
  Retroperitoneal   44/203                       37/328        **0.52 (0.33--0.83)**   **0.007**                                                       **0.54 (0.33--0.86)**                           **0.010**   32/313        49/218   **2.20 (1.36--3.55)**                                           **0.001**                                       **2.13 (1.32--3.45)**    **0.002**
  Mediastinum       36/203                       53/328        0.91 (0.58--1.44)       0.691                                                           0.89 (0.56--1.42)                               0.632       47/313        42/218   1.28 (0.82--2.01)                                               0.278                                           1.31 (0.83--2.06)        0.241
  Others            9/203                        15/328        1.03 (0.44--2.40)       0.943                                                           1.02 (0.44--2.37)                               0.970       16/313        8/218    0.72 (0.30--1.71)                                               0.453                                           0.71 (0.30--1.70)        0.442
  Clinical stage                                                                                                                                                                                                                                                                                                                                                                   
  I+II+4s           65/203                       58/328        **0.55 (0.37--0.82)**   **0.003**                                                       **0.55 (0.37--0.81)**                           **0.003**   50/313        73/218   **2.10 (1.41--3.13)**                                           **0.0003**                                      **2.11 (1.42--3.15)**    **0.0003**
  III+IV            46/203                       70/328        0.94 (0.62--1.42)       0.775                                                           1.00 (0.66--1.52)                               0.984       67/313        49/218   1.06 (0.70--1.58)                                               0.814                                           1.00 (0.66--1.51)        0.998

The significant results were in bold, if the 95% CI excluded 1 or *P* \<0.05. \*Adjusted for age and gender in logistic regress models.
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As shown in Table [3](#jcmm12836-tbl-0003){ref-type="table-wrap"}, at the prior probability level of 0.1 and FPRP threshold of 0.2, the association between *XPG* rs2094258 CT genotype and neuroblastoma risk remained noteworthy (FPRP = 0.136). Regarding stratified analysis, the significant increase in neuroblastoma risk for carrier of CT/TT genotypes was noteworthy in the subgroup with early‐stage tumour (FPRP = 0.186). Moreover, in the combined analysis, the associations between 2 and 3 risk genotypes and neuroblastoma risk also reached the FPRP threshold of \<0.2, and were considered deserving of attention: the association in the whole study population (FPRP = 0.154), the association in the subgroup with retroperitoneal tumour (FPRP = 0.127) and subgroup with early‐stage tumour (FPRP = 0.043).

###### 

False‐positive report probability analysis for the significant associations between neuroblastoma susceptibility and the rs2094258 C\>T and combined risk genotypes of the *XPG* gene

  Genotype               Crude OR (95% CI)    *P* [\*](#jcmm12836-note-0004){ref-type="fn"}   Statistical power[†](#jcmm12836-note-0004){ref-type="fn"}   Prior probability                               
  ---------------------- -------------------- ----------------------------------------------- ----------------------------------------------------------- ------------------- ----------- ------- ------- -------
  *XPG* rs2094258 C\>T                                                                                                                                                                                    
  CT *versus* CC         0.64 (0.46--0.89)    0.008                                           0.463                                                       0.050               **0.136**   0.634   0.946   0.994
  CT/TT *versus* CC      0.70 (0.52--0.96)    0.024                                           0.627                                                       0.103               0.255       0.791   0.974   0.997
  CT/TT *versus* CC                                                                                                                                                                                       
  Retroperitoneal        0.52 (0.33--0.83)    0.007                                           0.110                                                       0.153               0.351       0.856   0.984   0.998
  Stage I+II+4s          0.55 (0.37--0.82)    0.003                                           0.126                                                       0.071               **0.186**   0.716   0.962   0.996
  Risk genotypes                                                                                                                                                                                          
  2--3 *versus* 0--1     1.48 (1.10--2.01)    0.011                                           0.530                                                       0.057               **0.154**   0.666   0.953   0.995
  \>18                   1.49 (1.003--2.21)   0.049                                           0.500                                                       0.206               0.437       0.895   0.989   0.999
  Females                1.74 (1.08--2.80)    0.022                                           0.271                                                       0.195               0.421       0.889   0.988   0.999
  Retroperitoneal        2.20 (1.36--3.55)    0.001                                           0.074                                                       0.046               **0.127**   0.615   0.942   0.994
  Stage I+II+4s          2.10 (1.41--3.13)    0.0003                                          0.060                                                       0.015               **0.043**   0.333   0.834   0.981

The significant results were in bold, if the 95% CI excluded 1 or *P* \<0.05. \*Chi‐squared test was used to calculate the genotype frequency distributions. ^†^Statistical power was calculated using the number of observations in the subgroup and the OR and *P*‐values in this table.
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Genotype‐based mRNA expression analysis {#jcmm12836-sec-0011}
---------------------------------------

Results of the genotype‐based *XPG* mRNA expression analysis for rs2094258 C\>T and rs1047768 T\>C polymorphisms were shown in Table [4](#jcmm12836-tbl-0004){ref-type="table-wrap"}. We found the *XPG* mRNA expression levels in rs2094258 CT genotype carriers were significantly elevated when compared to the CC genotype carriers in Africans (*P* = 0.004) and Chinese subjects (*P* = 0.044). We also found a higher *XPG* mRNA expression for rs2094258 CT/TT genotype carriers for Africans (*P* = 0.005) and Chinese subjects (*P* = 0.027). For all subjects, we found a trend toward increased *XPG* mRNA expression (*P* = 0.074). These results were consistent with our findings from the association study. The decreased neuroblastoma susceptibility might be partially attributed to the decrease in *XPG* mRNA expression levels. As to the rs1047768 T\>C polymorphism, we only found significantly higher expression in the CC and CT/CC genotype carriers than in the TT genotype carriers for all the mixed subjects (*P* = 0.029 and *P* = 0.040, respectively).

###### 

*XPG* mRNA expression by the genotypes of rs2094258 C\>T and rs1047768 T\>C, using genotype data from the HapMap (<http://hapmap.ncbi.nlm.nih.gov/>)[\*](#jcmm12836-note-0005){ref-type="fn"} and mRNA expression data from SNPexp (<http://app3.titan.uio.no/biotools/help.php?app5snpexp>)

  Population   rs2094258 C\>T   rs1047768 T\>C                                                                     
  ------------ ---------------- ---------------- ------------- -- ----------- ----- ------------- ------------- -- -------
  CEU          CC               56               9.69 ± 0.22      0.701       TT    19            9.65 ± 0.29      0.617
  CT           29               9.69 ± 0.24      0.897            TC          44    9.69 ± 0.21   0.541            
  TT           5                9.79 ± 0.33      0.415            CC          27    9.72 ± 0.22   0.370            
  Dominant     34               9.70 ± 0.25      0.889            Dominant    71    9.71 ± 0.21   0.486            
  Recessive    85               9.69 ± 0.22      0.403            Recessive   63    9.68 ± 0.24   0.449            
  YRI          CC               61               9.79 ± 0.15      **0.016**   TT    6             9.73 ± 0.10      0.320
  CT           27               9.90 ± 0.19      **0.004**        TC          40    9.83 ± 0.19   0.226            
  TT           2                9.83 ± 0.13      0.757            CC          44    9.84 ± 0.15   0.087            
  Dominant     29               9.90 ± 0.19      **0.005**        Dominant    84    9.83 ± 0.17   0.140            
  Recessive    88               9.83 ± 0.17      0.994            Recessive   46    9.82 ± 0.18   0.480            
  CHB          CC               19               9.77 ± 0.21      **0.027**   TT    25            9.84 ± 0.21      0.850
  CT           23               9.90 ± 0.21      **0.044**        TC          16    9.87 ± 0.23   0.674            
  TT           3                9.96 ± 0.16      0.143            CC          4     9.81 ± 0.15   0.785            
  Dominant     26               9.91 ± 0.20      **0.027**        Dominant    20    9.86 ± 0.22   0.784            
  Recessive    42               9.84 ± 0.21      0.349            Recessive   41    9.85 ± 0.22   0.707            
  JPT          CC               11               9.64 ± 0.18      0.675       TT    34            9.67 ± 0.20      0.951
  CT           29               9.68 ± 0.19      0.639            TC          9     9.68 ± 0.18   0.859            
  TT           5                9.74 ± 0.25      0.410            CC          2     9.71 ± 0.13   0.785            
  Dominant     34               9.68 ± 0.20      0.549            Dominant    11    9.69 ± 0.17   0.789            
  Recessive    40               9.67 ± 0.19      0.445            Recessive   43    9.67 ± 0.19   0.792            
  All          CC               147              9.74 ± 0.19      0.074       TT    84            9.72 ± 0.23      0.087
  CT           108              9.78 ± 0.23      0.121            TC          109   9.77 ± 0.21   0.149            
  TT           15               9.81 ± 0.25      0.212            CC          77    9.79 ± 0.18   **0.029**        
  Dominant     123              9.79 ± 0.23      0.084            Dominant    186   9.78 ± 0.20   **0.040**        
  Recessive    255              9.76 ± 0.21      0.387            Recessive   193   9.75 ± 0.22   0.081            

The significant results were in bold, if the 95% CI excluded 1 or *P* \<0.05. \*Genotyping data and mRNA expression levels for *XPG* by genotypes were obtained from the HapMap phase II release 23 data from EBV‐transformed lymphoblastoid cell lines from 270 individuals. ^†^Two‐side Student\'s *t*‐test within the stratum. ^‡^ *P*‐values for the trend test of *XPG* mRNA expression among three genotypes for each SNP from a general linear model.
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Discussion {#jcmm12836-sec-0012}
==========

In the present hospital‐based case--control study, we explored the associations between five potentially functional polymorphisms in the *XPG* gene and the risk of neuroblastoma. We observed significant association between rs2094258 C\>T polymorphism and neuroblastoma susceptibility among Southern Chinese children. We found that individuals with rs2094258 CT and CT/TT genotypes were at significantly decreased neuroblastoma risk when compared with those with the CC genotype. We also found that the 2--3 risk genotype carriers had a significantly higher risk of neuroblastoma than the 0--1 risk genotype carriers. The FPRP analysis strengthened the significant associations, while genotype‐based mRNA expression analysis further provided biological evidence for our findings.

The human *XPG* gene is located on chromosome 13q33 and comprises a 30‐kb coding region with 15 exons and 14 introns. This gene encodes a 1186 amino acid structure‐specific endonuclease [33](#jcmm12836-bib-0033){ref-type="ref"}. XPG protein takes part in the transcription‐coupled repair [34](#jcmm12836-bib-0034){ref-type="ref"}, as well as the global genomic NER [35](#jcmm12836-bib-0035){ref-type="ref"}. It also plays an important role in RNA transcription through the interaction with other transcription activator complexes. Improper repair of DNA damage may lead to mutagenesis and cell death [36](#jcmm12836-bib-0036){ref-type="ref"}, [37](#jcmm12836-bib-0037){ref-type="ref"}. The XPG protein can cleave damaged oligonucleotide at the 3′ end. It also cooperates with the XPF/ERCC1 complex that excises damaged oligonucleotide at the 5′ end during NER process. Finally, this protein can stabilize the binding of DNA repair complex to damaged DNA [38](#jcmm12836-bib-0038){ref-type="ref"}, [39](#jcmm12836-bib-0039){ref-type="ref"}, [40](#jcmm12836-bib-0040){ref-type="ref"}. The sequence variations in the DNA repair genes may alter DNA repair capacity, consequentially causing inter‐individual differences in the predisposition to cancer [41](#jcmm12836-bib-0041){ref-type="ref"}. The *XPG* gene is highly polymorphic. According to the dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP>), there are at least 2432 identified SNPs in the *XPG* gene region, and 654 of them are coding region SNPs. SNPs may lead to the encoded amino acids changes (non‐synonymous), may be silent (synonymous) or may occur in non‐coding regions (transcription factor binding sites or miRNA binding sites). The non‐synonymous SNPs may affect gene function and phenotype and predispose to diseases [42](#jcmm12836-bib-0042){ref-type="ref"}. The most widely investigated SNP in the *XPG* gene is rs17655G\>C, which leads aspartate to histidine alteration at codon 1104 [24](#jcmm12836-bib-0024){ref-type="ref"}. The association with Asp1104His polymorphism has been widely investigated in different types of cancers, including breast cancer, skin cancer, lung cancer, bladder cancer, head and neck cancer, colorectal cancer and non‐Hodgkin lymphoma [24](#jcmm12836-bib-0024){ref-type="ref"}.

Moreover, three potentially functional *XPG* polymorphisms (rs2094258 C\>T, rs2296147 T\>C and rs873601G\>A) were studied for the association with gastric cancer in a case--control study with 1125 cases and 1196 controls by He *et al*. [26](#jcmm12836-bib-0026){ref-type="ref"}. They found that the rs873601G\>A polymorphism (located in the 3′ UTR) was significantly associated with increased gastric cancer risk. They also found that the rs873601 A allele were associated with decreased mRNA expression. Zhu *et al*. [43](#jcmm12836-bib-0043){ref-type="ref"} also explored the association between these three polymorphisms and oesophageal squamous cell carcinoma (ESCC) susceptibility. They reported a significant association between the rs2296147 C allele and decreased ESCC susceptibility. Duan *et al*. [27](#jcmm12836-bib-0027){ref-type="ref"} explored the association of rs751402 C\>T and rs2296147 T\>C polymorphisms with gastric cancer in 403 cases and 403 controls. They found that both of two polymorphisms were associated with an increased gastric cancer risk. Yang *et al*. [44](#jcmm12836-bib-0044){ref-type="ref"} also genotyped these three polymorphisms in 337 stomach cancer cases and 347 controls. Data showed that the rs2296147 T\>C polymorphism was associated with decreased gastric cancer risk, while the rs2094258 C\>T polymorphism was associated with increased gastric cancer risk. In a study with 241 prostate cancer cases and 264 controls [45](#jcmm12836-bib-0045){ref-type="ref"}, the rs2296147 T\>C polymorphism was shown to associate with increased prostate cancer risk. However, the association with the rs2094258 C\>T polymorphism was not replicated in the same study. In the study with 325 breast cancer cases and 325 controls, Na *et al*. [46](#jcmm12836-bib-0046){ref-type="ref"} tested all of the five polymorphisms included in our study and found significant association between the rs2094258 TT genotype and increased breast cancer risk. Sun *et al*. [47](#jcmm12836-bib-0047){ref-type="ref"} failed to find any significant association between rs2094258 C\>T polymorphism and laryngeal cancer susceptibility with a total of 271 cases and 271 controls.

To the best of our knowledge, this is the first investigation on the association between *XPG* gene polymorphisms and neuroblastoma susceptibility. In this study, we found the rs2094258 C\>T polymorphism was associated with decreased neuroblastoma risk. This protective effect of the SNP may be ascribed to the resultant up‐regulation of the *XPG* gene expression. As predicted by SNPinfo (Table S2), the rs2094258 C\>T polymorphism is located in the 5′ near region of *XPG* gene and is within a transcription factor binding site. The C\>T alteration may lead to an increase in the *XPG* mRNA expression (Table [4](#jcmm12836-tbl-0004){ref-type="table-wrap"}) in Chinese subjects as well as in overall individuals. The rs2094258 C\>T polymorphism‐induced increase in *XPG* gene expression may enhance an individual\'s DNA repair capacity, which support the protective association between the rs2094258 T allele and decreased neuroblastoma. Previous studies reported that this polymorphism could increase or decrease cancer risk. The different results may be ascribed to the fact that different cancers may have different environment exposures as well as the difference in sampling in each investigation. Besides, gene--environment interaction may also play important roles in the tumourigenesis [48](#jcmm12836-bib-0048){ref-type="ref"}. It\'s important to perform FPRP analysis to verify if the significant findings were chance findings or really noteworthy. Moreover, further functional studies are needed to explore the specific mechanisms by which this polymorphism modifies cancer susceptibility.

Though this is the first and largest study to investigate the association of DNA repair gene polymorphisms with neuroblastoma in Chinese children, several limitations in this study should be addressed. First, only 256 cases and 531 controls were included in this study. The relatively small sample size, especially for the cases, may result in limited statistical power. Second, selection bias may exist; since all the subjects were enrolled only from our hospital and restricted to a Chinese Han population, we might miss a larger number of neuroblastoma cases who did not visit our hospital for treatment during the same period. Third, we only included five potentially functional polymorphisms in this study. In the future, all functional SNPs in *XPG* gene should be investigated in different ethnicities, which will yield a meaningful conclusion. Finally, some important information was not available in our study, such as the paternal exposures, living environment and dietary intake for the included children, which limited our ability to perform gene--environmental interactions analysis in neuroblastoma susceptibility.

In conclusion, this study provides evidence that potentially functional polymorphisms in the *XPG* gene, especially the rs2094258 C\>T polymorphism, may contribute to neuroblastoma susceptibility in Southern Chinese children. However, further prospective studies with larger sample size involving different ethnicities, as well as further functional studies, are needed to confirm our findings.
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**Table S1** Frequency distribution of selected characteristics in neuroblastoma patients and controls.

**Table S2** Potential function of the five selected SNPs in *XPG* gene as predicted by SNPinfo software.
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Click here for additional data file.
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